Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10306MR)

This product GTTS-WQ10306MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10306MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8460MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ3599MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ2024MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ6234MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CR57
GTTS-WQ12420MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ6754MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DS 992
GTTS-WQ12737MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ1964MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AGS-15E
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW